Talphera, Inc. (TLPH)
After hours:
| Previous Close | 0.9202 |
| Open | 0.9201 |
| Bid | 0.8679 x 200 |
| Ask | 0.9375 x 100 |
| Day's Range | 0.8500 - 0.9399 |
| 52 Week Range | 0.4300 - 1.6100 |
| Volume | |
| Avg. Volume | 64,301 |
| Market Cap | 15.294M |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference and will be taking 1x1 meetings.
- PR Newswire
Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study.
- PR Newswire
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update.
